VYGR
VYGR
NASDAQ · Biotechnology

Voyager Therapeutics Inc

$2.70
+0.02 (+0.75%)
As of Sep 28, 10:14 PM ET ·
Financial Highlights (FY 2026)
Revenue
40.49M
Net Income
-120,051,824
Gross Margin
—
Profit Margin
-296.5%
Rev Growth
-0.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 40.1% 40.1%
Operating Margin -326.6% -293.9% -0.3% -0.3%
Profit Margin -296.5% -281.7% -0.3% -0.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 40.49M 40.66M 42.57M 38.58M
Gross Profit — — 17.06M 15.46M
Operating Income -132,211,571 -119,504,282 -137,767 -112,961
Net Income -120,051,824 -108,513,248 -129,666 -108,514
Gross Margin — — 40.1% 40.1%
Operating Margin -326.6% -293.9% -0.3% -0.3%
Profit Margin -296.5% -281.7% -0.3% -0.3%
Rev Growth -0.4% -0.4% +21.1% -3.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.86M 64.95M
Total Equity — — 186.28M 172.57M
D/E Ratio — — 0.31 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -128,138,461 -122,257,244 -158,434 -135,051
Free Cash Flow — — -114,389 -110,539